Reportable Segment Information (Tables)

12 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Segment Revenue, Operating Income and Depreciation and Amortization

The tables below present segment revenue, operating income from continuing operations and depreciation and amortization, for the years ended September 30, as follows (in thousands):

	2017			2016			2015
Revenue:
Medical Device	$	53,983		$	53,202		$	45,944
In Vitro Diagnostics		19,129			18,164			15,954
Total revenue	$	73,112		$	71,366		$	61,898
Operating income (loss):
Medical Device	$	6,902		$	16,975		$	21,192
In Vitro Diagnostics		8,293			7,115			4,484
Total segment operating income		15,195			24,090			25,676
Corporate		(8,092	)		(7,231	)		(6,587	)
Total operating income	$	7,103		$	16,859		$	19,089
Depreciation and amortization:
Medical Device	$	4,453		$	3,261		$	1,138
In Vitro Diagnostics		412			789			873
Corporate		690			823			794
Total depreciation and amortization	$	5,555		$	4,873		$	2,805

Revenue from Major Customers

Revenue from customers that equaled or exceeded 10% of total revenue was as follows for the years ended September 30:

	2017			2016			2015
Medtronic		18	%		25	%		26	%

Geographic Revenue and Long-lived Assets

Geographic revenue was as follows for the years ended September 30:

	2017			2016			2015
Domestic		77	%		79	%		77	%
Foreign		23	%		21	%		23	%

Long-lived assets, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, by country were as follows as of September 30:

	2017		2016
U.S.	$	20,949	$	21,543
Ireland		22,555		20,583